Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis

Recruiting now · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Radiation-induced Dermatitis

In brief

To evaluate the efficacy and safety of topical Periplaneta americana-derived Meilian Fuxin Solution for the prevention of radiation dermatitis in patients undergoing radiotherapy.

Key facts

Study ID
NCT07353671
Run by
West China Hospital
People needed
60
Starts
2026-03-01
Expected to finish
2027-06-30
Last updated by the study team
2026-03-25

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.